Literature DB >> 25125464

Increased tau phosphorylation and aggregation in the hippocampus of mice overexpressing corticotropin-releasing factor.

Shannon N Campbell1, Cheng Zhang1, Louise Monte1, Allyson D Roe1, Kenner C Rice2, Yvette Taché3, Eliezer Masliah4, Robert A Rissman1.   

Abstract

Clinical and basic science research suggests that stress and/or changes in central stress signaling intermediates may be involved in Alzheimer's disease (AD) pathogenesis. Although the links between stress and AD remain unsettled, data from our group and others have established that stress exposure in rodents may confer susceptibility to AD pathology by inducing hippocampal tau phosphorylation (tau-P). Work in our laboratory has shown that stress-induced tau-P requires activation of the type-1 corticotropin-releasing factor receptor (CRFR1). CRF overexpressing (CRF-OE) mice are a model of chronic stress that display cognitive impairment at 9-10 month of age. In this study we used 6-7 month old CRF-OE mice to examine whether sustained exposure to CRF and stress steroids would impact hippocampal tau-P and kinase activity in the presence or absence of the CRFR1-specific antagonist, R121919, given daily for 30 days. CRF-OE mice had significantly elevated tau-P compared to wild type (WT) mice at the AT8 (S202/T204), PHF-1 (S396/404), S262, and S422 sites. Treating CRF-OE mice with R121919 blocked phosphorylation at the AT8 (S202/T204) and PHF-1 (S396/404) sites, but not at the S262 and S422 sites and reduced phosphorylation of c-Jun N Terminal Kinase (JNK). Examination of hippocampal extracts from CRF-OE mice at the ultrastructural level revealed negatively stained round/globular aggregates that were positively labeled by PHF-1. These data suggest critical roles for CRF and CRFR1 in tau-P and aggregation and may have implications for the development of AD cognitive decline.

Entities:  

Keywords:  Alzheimer's disease; corticotropin-releasing factor (CRF); corticotropin-releasing factor receptor (CRFR); electron microscopy; hippocampus; immunohistochemistry; stress; tau phosphorylation (tau-P); western blot

Mesh:

Substances:

Year:  2015        PMID: 25125464      PMCID: PMC4258165          DOI: 10.3233/JAD-141281

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  66 in total

1.  Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse.

Authors:  E Planel; K Yasutake; S C Fujita; K Ishiguro
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

2.  Corticotropin-releasing factor receptor-dependent effects of repeated stress on tau phosphorylation, solubility, and aggregation.

Authors:  Robert A Rissman; Michael A Staup; Allyson Roe Lee; Nicholas J Justice; Kenner C Rice; Wylie Vale; Paul E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

Review 3.  Corticotropin-releasing factor signaling and visceral response to stress.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Exp Biol Med (Maywood)       Date:  2010-10

4.  Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor.

Authors:  S C Heinrichs; M P Stenzel-Poore; L H Gold; E Battenberg; F E Bloom; G F Koob; W W Vale; E M Pich
Journal:  Neuroscience       Date:  1996-09       Impact factor: 3.590

5.  Granular tau oligomers as intermediates of tau filaments.

Authors:  Sumihiro Maeda; Naruhiko Sahara; Yuko Saito; Miyuki Murayama; Yuji Yoshiike; Hyonchol Kim; Tomohiro Miyasaka; Shigeo Murayama; Atsushi Ikai; Akihiko Takashima
Journal:  Biochemistry       Date:  2007-03-06       Impact factor: 3.162

6.  Stress-induced hyperphosphorylation of tau in the mouse brain.

Authors:  Yasuhiro Okawa; Koichi Ishiguro; Shinobu C Fujita
Journal:  FEBS Lett       Date:  2003-01-30       Impact factor: 4.124

7.  Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.

Authors:  N Sahara; S Maeda; Y Yoshiike; T Mizoroki; S Yamashita; M Murayama; J-M Park; Y Saito; S Murayama; A Takashima
Journal:  J Neurosci Res       Date:  2007-11-01       Impact factor: 4.164

8.  Characterization of the genomic corticotropin-releasing factor (CRF) gene from Xenopus laevis: two members of the CRF family exist in amphibians.

Authors:  M P Stenzel-Poore; K A Heldwein; P Stenzel; S Lee; W W Vale
Journal:  Mol Endocrinol       Date:  1992-10

9.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

10.  Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.

Authors:  Amy K Clippinger; Simon D'Alton; Wen-Lang Lin; Tania F Gendron; John Howard; David R Borchelt; Ashley Cannon; Yari Carlomagno; Paramita Chakrabarty; Casey Cook; Todd E Golde; Yona Levites; Laura Ranum; Patrick J Schultheis; Guilian Xu; Leonard Petrucelli; Naruhiko Sahara; Dennis W Dickson; Benoit Giasson; Jada Lewis
Journal:  Acta Neuropathol       Date:  2013-05-11       Impact factor: 17.088

View more
  25 in total

1.  Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model.

Authors:  Cheng Zhang; Ching-Chang Kuo; Setareh H Moghadam; Louise Monte; Kenner C Rice; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Reproductive Stage and Modulation of Stress-Induced Tau Phosphorylation in Female Rats.

Authors:  Danielle Steinmetz; Eugenia Ramos; Shannon N Campbell; Teresa Morales; Robert A Rissman
Journal:  J Neuroendocrinol       Date:  2015-11       Impact factor: 3.627

Review 3.  Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain.

Authors:  Sherie Ma; Craig M Smith; Anna Blasiak; Andrew L Gundlach
Journal:  Br J Pharmacol       Date:  2016-12-04       Impact factor: 8.739

4.  Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease.

Authors:  Shannon N Campbell; Cheng Zhang; Allyson D Roe; Nickey Lee; Kathleen U Lao; Louise Monte; Michael C Donohue; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

6.  Tau Mislocation in Glucocorticoid-Triggered Hippocampal Pathology.

Authors:  Sara Pinheiro; Joana Silva; Cristina Mota; João Vaz-Silva; Ana Veloso; Vítor Pinto; Nuno Sousa; João Cerqueira; Ioannis Sotiropoulos
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

Review 7.  Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review.

Authors:  Erwin Lemche
Journal:  Curr Genomics       Date:  2018-11       Impact factor: 2.236

8.  Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  Cheng Zhang; Ching-Chang Kuo; Setareh H Moghadam; Louise Monte; Shannon N Campbell; Kenner C Rice; Paul E Sawchenko; Eliezer Masliah; Robert A Rissman
Journal:  Alzheimers Dement       Date:  2015-11-07       Impact factor: 21.566

Review 9.  Stress induced neural reorganization: A conceptual framework linking depression and Alzheimer's disease.

Authors:  Jennifer A Ross; Gediminas Gliebus; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-08-10       Impact factor: 5.201

10.  Locus Coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease.

Authors:  Jennifer A Ross; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Neurobiol Stress       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.